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Extra-Aortic Identifiers to
Guide Genetic Testing in
Familial Thoracic Aortic
Aneurysms and
Dissections Syndromes
It Is All About the Company One Keeps*
Eloisa Arbustini, MD, Nupoor Narula, BS
Pavia, Italy
Familial thoracic aortic aneurysms and dissections (F-TAADs)
are a large group of autosomal dominant, clinically and
genetically heterogeneous diseases sharing TAADs as a
common phenotype and comprising variable combinations
and recurrence of extra-aortic traits (1–11). Genetic aneu-
rysmal syndromes can be suspected in subjects with a
positive family history or positive family screening results.
See page 397
The clinical screening provides the descriptive diagnosis
(aneurysm) of F-TAADs, whereas the specific diagnosis is
based on the identification of the genetic defect. Given the
genetic heterogeneity of TAAD (more disease genes may
cause similar phenotypes), the strategy for genetic testing
either could follow screening of all known disease genes or
could use extra-aortic clinical markers as a guide for genetic
testing. The extra-aortic identifiers include patent ductus
arteriosus (caused by mutations of MYH11) (2,3), iris
flocculi and variable skeletal or smooth muscle dysfunction
(mutations of ACTA2) (4–6), gastrointestinal diseases (de-
ects of MYLK) (7), early osteoarthritis and intracranial
saccular aneurysms (mutations of SMAD3) (8–10), juvenile
polyposis (defects of SMAD4) (11), and craniofacial abnor-
malities in Loeys-Dietz syndrome (LDS) 1 or Elhers-
Danlos (EDS)-like cutaneous characteristics in LDS2
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TGFBR2) (Fig. 1) (12). A small subgroup of patients
diagnosed with a fibrillin 1 mutation also may enter this
group of diseases that have aortic aneurysm as the only
major phenotypic trait (13,14). Similarly, a small proportion
of LDS1 and LDS2 patients may not show prominent
craniofacial traits or EDS-cutaneous features, and therefore
the clinical diagnosis may remain difficult (1). Genetic
testing in F-TAAD promises a specific diagnosis based on
the disease-causing gene and may allow a novel genetically
driven nosology that would generate a homogeneous cohort
of F-TAAD patients large enough to plan disease-specific
clinical trials.
Advantages of clinical and genetic diagnosis. Clinical
cascade screening of families of probands with TAADs can
be performed easily, independently on the identification of
the causative mutation. Even before genetic testing, the
diagnosis of TAADs in young patients without risk factors
calls for cascade clinical screening of relatives. Because
F-TAADs syndromes are autosomal dominant, the proba-
bility of diagnosing early disease in relatives is at least 50%.
This simple approach provides the rationale for family-
tailored clinical monitoring programs that may save lives
and may offer standard of care for these families.
When the disease-causing mutation is identified in the
proband, the immediate advantage is the opportunity to
perform cascade genetic screening in relatives and to iden-
tify family members who are at risk, so that identified family
members can be monitored closely and treated medically to
prevent the occurrence or at least delay, the progressive
aortic dilatation. For example, the use of angiotensin recep-
tor blockers (ARBs) to interfere with transforming growth
factor (TGF)-1 signaling has been reported to retard the
neurysmal dilatation in experimental Marfan syndrome
MFS) (15). While waiting for evidence-based data from
ngoing clinical trials in MFS (16,17) and assuming that
RBs interfere with TGF-1 (18), ARBs may be of benefit
for TAADs caused by defects in genes playing their role in
the TGF- pathway (including gene coding for structural or
regulatory proteins of the smooth muscle cells of vessel
walls).
Aneurysm-osteoarthritis syndrome. In this issue of the
Journal, van der Linde et al. (19) describe the cardiovascular
phenotype of 44 patients from 7 families diagnosed with the
novel autosomal dominant aneurysms-osteoarthritis syn-
drome (AOS), characterized by aortic aneurysms, arterial
tortuosity, and early osteoarthritis caused by mutation of the
SMAD3 gene (MIM*603109) (8–10,20). Smad are intra-
cellular proteins that transduce extracellular signals from the
cell surface receptors to the nucleus, where they regulate
TGF gene transcription (21).
In this AOS series (19), 71% of the patients had aortic
root aneurysm, 18% had aneurysms in other thoracoab-
dominal arteries, 48% showed arterial tortuosity, and 56%
had multiple aneurysms and cerebrovascular abnormalities.
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July 31, 2012:404–7 SMAD3 Mutations and TAADs with OsteoarthritisAll adult patients with TAADs deserve echocardiography,
ending with total-body computed tomography or magnetic
resonance imaging, to monitor the aortic size and rate of
growth of the aneurysms (19). Early osteoarthritis seems to
be a highly specific marker of the disease, affecting up to
100% of patients (8). In the current study, more than 90%
of patients had early osteoarthritis mostly affecting the
spine, hands and wrists, and knees, with painful joints in
85% (19). Accordingly, clinical evaluation of joints in
patients with TAADs should be performed routinely. Mean
age at diagnosis of osteoarhtritis coincided with the age at
diagnosis of TAADs (42 years), with the youngest patient
diagnosed at the age of 12 years. Variable skeletal and
craniofacial traits observed in AOS, such as pes planus
(91%), scoliosis (61%), hypertelorism (31%), abnormal
palate (54%), abnormal uvula (52%), or hernia inguinalis
Figure 1 Flow Chart Illustrating the Diagnostic Workup for Clin
Several issues are still open about genetic testing, in particular in sporadic thorac
disease genes provides the basis for implementing disease-specific diagnostic wo
(Next Generation Sequencing [NGS] platforms) will rapidly modify the current scen
ease genes. In parallel, clinical phenotypes associated with mutations of the diffeor umbilicalis (43%), occur variably in LDS1 patients(AOS is also known as LDS1C [MIM#613795]), as well
as in MFS and in TAADs associated with mutations of
other genes. The authors suggest that AOS should be
suspected in TAAD patients without molecular diagnosis
or known cause and that the SMAD3 gene should be
tested in these patients.
Warning about the high risk of aortic dissection in new
aneurysmal syndromes. Similar to the TAADs caused by
mutations of ACTA2, MYH11, MYLK, SMAD4, TGFBR1,
and TGFBR2 (1–7,11), TAADs caused by SMAD3 muta-
tions show a clinical outcome characterized by high mor-
tality resulting from aortic dissection in both severely and
mildly dilated aortas (8–10,19,20). The risk of dissection in
patients with mildly dilated aortas opens a new clinical
scenario in which prevention of catastrophic events would
become more difficult than in conditions such as MFS, in
nd Genetic Evaluation of TAADs
ic aneurysms and dissections (TAADs). In familial TAADs, existing knowledge on
nd genetic testing. Advanced technologies for deoxyribonucleic acid sequencing
d increase the series of TAADs specifically diagnosed on the basis of the dis-
sease genes will be confirmed.ical a
ic aort
rkup a
ario an
rent diwhich the risk usually occurs in patients with aortic dilata-
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criteria for stratification of the risk of aortic dissection are
needed to establish the correct timing for preventive aortic
surgery; these criteria should include aortic diameters, dis-
ease gene and mutation, family history of dissection, as well
as other data such as rate of progression of the aneurysm and
the presence of risk factors such as hypertension. van der
Linde et al. examined aortic stiffness as a disease marker
independent of the aneurysm and also N-terminal brain
natriuretic peptide as a protective mechanism against the
emergence of left ventricle hypertrophy (19). In AOS
caused by defects of the SMAD3 gene, as well as in TAADs
caused by defects of ACTA2 or MYLK, the observation that
issection occurred in mildly dilated aortas calls for an
rgent need to identify families at high risk of aortic
upture. However, the overestimation of the risk of dissec-
ion could lead patients with mild aortic dilatation to
nwarranted surgery. The number of dissections that oc-
urred in mildly dilated aortas is low, and more data on the
atural history of these aneurysms in patients appropriately
ared for and followed up in referral centers are not
vailable. Multicenter observational surveys should be un-
ertaken before developing recommendations for preventive
urgery. While waiting for evidence-based clinical data, the
uthors recommend the application of surgical recommen-
ations for LDS (22), with valve-sparing aortic root replace-
ent as the intervention of choice (23). As discussed above,
lthough data from randomized clinical trials are not avail-
ble, angiotensin receptor blockers could contribute to the
elay of the progression of aneurysmal dilatation and could
ontrol hypertension; however, the latter is rare in young
ndividuals with TAADs.
xtra-aortic vascular events. Data on cerebrovascular
vents in TAADs patients with mutations of different genes
re increasing. Regalado et al. (10) described the association
etween TAADs and saccular intracranial aneurysm, and
ow the current study (19) nicely documents the high
revalence of intracranial aneurysms frequently associated
ith arterial tortuosity. The risk of stroke therefore has to
e considered as a new clinical entity in TAADs syn-
romes. Collaborative efforts between cardiologists and
eurosurgeons should be a new avenue in clinical research
o identify patients carrying double aortic and cerebral
isk of arterial dissection or rupture and should generate
pidemiologic data that support disease-specific diagnos-
ic workup.
In conclusion, the series of AOS patients described in this
ssue of the Journal highlights important clinical messages.
irst, each patient with TAADs of unknown cause should
e considered to be potentially affected by AOS: the simple
linical evaluation of joints may reinforce the clinical suspi-
ion and addresses genetic testing for SMAD3. Second,
elatives of patients with TAADs, either caused by muta-
ions of SMAD3 or by other disease genes, should undergo
linical screening; when the causative mutation is identified,
ascade genetic testing is indicated in families. Third, thelinical impact of the diagnosis of AOS goes beyond
AADs-related risk and also includes risk of cerebrovascu-
ar events as well as the risk of abdominal aneurysms.
inally, although waiting for evidence-based data, TGF
ntagonists could be useful for delaying the progression of
ortic dilatation; temporary recommendations for preventive
urgery are as in LDS. Overall, the first major responsibility
f cardiologists is to identify family members at risk when
reating probands with TAADs of unknown cause or with
erebral or abdominal aneurysms.
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